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Available online 12 May 2008The genus Alphavirus contains members that threaten human health, both as natural pathogens and as
potential biological weapons. Peptide-conjugated phosphorodiamidate morpholino oligomers (PPMO) enter
cells readily and can inhibit viral replication through sequence-speciﬁc steric blockade of viral RNA. Sindbis
virus (SINV) has low pathogenicity in humans and is regularly utilized as a model alphavirus. PPMO targeting
the 5′-terminal and AUG translation start site regions of the SINV genome blocked the production of infectious
SINV in tissue culture. PPMO designed against corresponding regions in Venezuelan equine encephalitis virus
(VEEV) were likewise found to be effective in vitro against several strains of VEEV. Mice treated with PPMO
before and after VEEV infection were completely protected from lethal outcome while mice receiving only
post-infection PPMO treatment were partially protected. Levels of virus in tissue samples correlated with
animal survival. Uninfected mice suffered no apparent ill-effects from PPMO treatment. Thus, PPMO appear
promising as candidates for therapeutic development against alphaviruses.
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The genus Alphavirus in the family Togaviridae consists of 28
viruses, most of which cycle betweenmosquito vectors and vertebrate
hosts. Several alphaviruses, including Venezuelan equine encephalitis
virus (VEEV), Eastern equine encephalitis virus (EEEV),Western equine
encephalitis virus (WEEV), O'nyong-nyong virus and Chikungunya
virus, can cause severe disease in humans, that typically includes fever
and neurological sequelae (Grifﬁn, 2007). Of these, VEEV is the most
important human pathogen, with several recent outbreaks consisting
of hundreds of thousands of cases occurring mostly in Latin America
(Weaver et al., 2004). Furthermore, EEEV, WEEV, and VEEV are
considered bioterrorist threats because they cause severe disease in
humans, can be produced in large quantity and/or are potentially
transmitted by aerosol (Hawley and Eitzen, 2001; Sidwell and Smee,
2003). Veterinary vaccines of varying quality against EEEV,WEEV, and
VEEV are commercially available, but only IND preparations areUniversity of Texas Medical
019, USA. Fax: +1409 747 0762.
iego, CA, USA.
l rights reserved.approved for human use and their availability is limited to military
and laboratory personnel. No therapeutic for alphavirus-induced
disease exists, although supportive treatment and anti-inﬂammatory
drugsmay be beneﬁcial. Recently short interfering RNAs (siRNAs) have
been shown to be effective against the alphaviruses Semliki Forest
virus (Caplen et al., 2002) and VEEV (O'Brien, 2006), in cell cultures,
and against O'nyong-nyong virus replication in its natural mosquito
vector, Anopheles gambiae (Keene et al., 2004).
Alphaviruses have a single positive-stranded RNA genome of
approximately 12 kb that codes for two polyproteins that are
processed to four nonstructural proteins and three structural proteins,
respectively. The open reading frames are ﬂanked by 5′ and 3′
untranslated regions (UTRs) of approximately (∼) 60 and ∼300
nucleotides, respectively. The nonstructural proteins are translated
from the full-length genomic RNA and are utilized to produce a full-
length negative-strand antigenomic RNA. The negative-strand inter-
mediate is used as template to produce both full-length positive-
strand, and, using a 24 nucleotide internal promoter, a ∼4 kb
subgenomic RNA is produced, which is identical in sequence to the
3′ terminal third of the genomic RNA. The structural proteins are
translated from the subgenomic RNA. Both genomic and subgenomic
RNA are 5′ capped and 3′ polyadenylated. Sindbis virus (SINV) has
been extensively used as a model alphavirus because of its low
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and molecular biology that is considered representative of the genus
(Strauss and Strauss, 1994).
Antisense oligomers of various structural types have been used to
interfere with gene expression of several human viral pathogens
(Schubert and Kurreck, 2006), and a phosphorothioate oligonucleotide
designed to target mRNA of cytomegalovirus (CMV) that is intended to
treat CMV-induced retinitis is an approved drug (De Clercq, 2004).
However, antisense therapeutic technology continues to be hampered
by limitations in both oligomer stability and delivery to RNA targets
within relevant cells (Kurreck, 2003). Phosphorodiamidate morpho-
lino oligomers (PMO) are a class of oligonucleotide-like antisense
agents that possess the same four bases as DNA, but contain a different
backbone. The deoxyribose ring and phosphodiester linkage of DNA
are replaced by a morpholine ring and phosphorodiamidate linkage in
PMO (Summerton and Weller, 1997). PMO are nonionic, are stable in
cellular extracts and human serum (Nelson et al., 2005; Youngblood
et al., 2007) and typically are synthesized to a length of 20–25 subunits.
The PMO mechanism of antisense action is via steric-blocking of
complementary RNA sequence (Stein et al.,1997), and thus differs from
that of antisense agents based on DNA chemistry, which induce RNase
H-mediated cleavage of the RNA strand of a RNA–DNAduplex, or RNAi/
siRNA involving double-stranded agents that recognize target mRNA
and induce its degradation by cellular proteins (Masiero et al., 2007).
PMO covalently conjugated to a cell-penetrating peptide (CPP) can be
delivered efﬁciently into cells (Deas et al., 2005; Moulton et al., 2004;
Yuan et al., 2006; Zhang et al., 2006). CPP-PMO are water-soluble and
have been shown to generate potent inhibition of several RNA viruses,
including dengue virus (Holden et al., 2006; Kinney et al., 2005), West
Nile virus (Deas et al., 2005), SARS Coronavirus (Neuman et al., 2005),
Equine Arterivirus (van den Born et al., 2005) and inﬂuenza virus (Ge
et al., 2006) in cell culture, and Coxsackievirus B3 (Yuan et al., 2006),
Ebola virus (Enterlein et al., 2006), murine Coronavirus (Burrer et al.,
2007) andWest Nile virus (Deas et al., 2007) both in cell culture and in
mouse models. Two different CPP-conjugated PMO (PPMO), one
containing oligoarginine (P3) and one containing 6-aminohexanoic
acid (P7), have been utilized (Moulton et al., 2004; Abes et al., 2006). A
recent report documented that P7-conjugated PPMO are highly stable
in human serum for at least 2 hours (h), andmoderately stable for 24 h
(Youngblood et al., 2007).
In the present study, we ﬁrst evaluated six SINV-speciﬁc PPMO
designed to base pair with sequences in the four terminal regions
of the full-length genome or antigenome, the AUG translation startFig. 1. Location of PPMO target sites in alphavirus genome segments. A schematic representa
and 3′ untranslated regulatory regions (UTR) of alphavirus genomic (+) and antigenomic (−) R
E), and subgenomic promoter region of the antigenomic (labeled F), RNA. Sindbis virus (SIN
and sequences are shown in Table 1.site region of the polyprotein coding sequence for the nonstructural
proteins, and the subgenomic promoter region of the negative-strand
antigenome. We found that two PPMO, one targeting the 5′-terminal
sequence and the other targeting the ﬁrst functional AUG translation
start site regions of the genome, were effective in blocking viral
production. Subsequently, PPMO were designed to target the two
corresponding regions in VEEV. As for the SINV PPMO, VEEV-speciﬁc
PPMO were found to inhibit the replication of several VEEV strains in
cell cultures and were efﬁcacious in a murine model of VEE.
Results
Design of PPMO
Considerations in PPMO sequence design for this study included
our current understandingof the function of various alphavirus genetic
regions, and PPMOmechanism of action. Aswith other positive-strand
viruses that utilize cap-dependent translation, access of trans-acting
proteins to the 5′ terminal region of the genome is critical to alphavirus
capping reactions and the process of translation pre-initiation
(Vasiljeva et al., 2000). It has also been shown by mutational studies
that certain sequence and secondary structure requirements in the 5′
terminal region of the alphavirus genomemust be present for efﬁcient
viral replication to occur (Frolov et al., 2001; Gorchakov et al., 2004;
Niesters and Strauss,1990; Tsiang et al.,1988). The 3′ terminal region of
the antigenome has likewise been shown to play an integral role in
positive-strand synthesis (Frolov et al., 2001), perhaps through the
presence of a stem-loop structure corresponding to the inverse of that
present in the 5′ end of the genome. Speciﬁc sequence requirements in
the 19 nucleotide 3′ conserved sequence element (3′CSE) immediately
preceding the polyA tail are necessary for efﬁcient minus-strand
synthesis (Frolov et al., 2001). Another study reported high antiviral
activity from PPMO targeting the 5′ terminal region of the Equine
Arterivirus genome, andmoderate activity with PPMO targeting either
the 3′ terminus of the genome or 3′ terminus of the antigenome (van
den Born et al., 2005), although the 5′ end of the antigenome was not
included as a target. Other groups have also reported high efﬁcacy by
PPMO targeting the genomic 5′ terminal region of other positive-
strand viruses, including dengue (Kinney et al., 2005), West Nile virus
(Deas et al., 2005), porcine reproductive and respiratory syndrome
virus (Zhang et al., 2006) andmurine Coronavirus (Burrer et al., 2007).
The above reports documenting the importance of sequence and
structures in terminal regions of the alphavirus genome, alongwith thetion of the alphavirus genome is shown. PPMO were designed to target the terminal 5′
NA (labeled A–D), as well as the AUG translation start site region of the genomic (labeled
V)- and Venezuelan equine encephalitis virus (VEEV)-speciﬁc PPMO name designations
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the four termini of SINV genomic RNA (Fig. 1). Alphavirus subgenomic
(sg) RNA encoding the structural proteins is synthesized by internal
initiation on the genome-length negative-strand RNA. The minimal
sequence essential for promoter activity extends from nucleotide −19 to
+5 (in relation to the start codon of the sg positive-strand) and
corresponds to the genomic positive-strand sequence from nucleotides
7579 to 7602 in SINV (Levis et al.,1990).We therefore targeted this core-
promoter region in the antigenome, in an effort to interfere with the
synthesis of plus-strand sg RNA. The genomic 5′-most AUG codon isFig. 2. Effect of PPMO on cell viability. A) SINV PPMO. BHK cells were incubated with the 0.1, 0
(SINV 5′+, SINV AUG, or SINV sgP, see Table 1), or as a negative control, the P3-conjugated Scr
MTT assay (described in Materials andmethods), is expressed relative tomock-treated cells. B
PPMO (see Table 1), or as a negative control, the P7- or P7-AMCA-conjugated Scr PPMO (a ra
7.5 μm) and for different time points (0, 4, 10, 20, 24, 36, 48 h). The average of quadruplicate
shown. Two-way ANOVA (α=0.05) with Bonferroni post-test for pairwise comparison o
concentration was performed.required for translation initiation of the nonstructural proteins of
alphaviruses (Lemmet al.,1994). The regionﬂanking the translation start
site has been a favored target site for PMO mediated silencing of viral
(Enterlein et al., 2006; Neuman et al., 2005; van den Born et al., 2005)
and cellular (Heasman, 2002; Nasevicius and Ekker, 2000) mRNAs, and
was an obvious PPMO target selection. Three of the six sites we initially
chose to target with PPMO are regions of highly conserved sequence
either between alphavirus species, or between strains within a species:
(i) the CSE at the 3′ terminus of the genome (ii) the sg core-promoter
region and (iii) the 5′ terminal region (Lemm et al., 1994)..5, 1, 2.5, 5, 7.5, 10, or 20 μMof the indicated with the P3-conjugated SINV-speciﬁc PPMO
PPMO (a random nucleotide sequence), for 24 h. Reduction of cell viability, measured by
) VEEV PPMO. Vero cells were incubated with the P7- or P7-AMCA-conjugated VEEV 5′+
ndom nucleotide sequence) with a range of PPMO concentrations (0.1, 0.5, 1, 2.5, 5 and
treatments, measured by CellTiter-Blue® assay (described in Materials and methods), is
f PPMO-treated vs. untreated (“No PPMO”) controls by respective time point and
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The impact of P3-PPMOon cell viabilitywas evaluated byMTTassay
on BHK cells following 24h incubationwith the P3-conjugated PPMO –
SINV 5′+, SINV AUG, SINV sgP, and Scr – in the range of 0.1–20 μM
(Fig. 2A). Cell viability readings for all PPMO at all concentrations
tested, relative to vehicle-treated cells, were ∼80% or greater. Similar
cytotoxicity evaluation was carried out for the P7- and the P7-AMCA-
conjugated PPMO (VEEV 5′+ and Scr) (Fig. 2B). Viability assay was
performed in quadruplicate at multiple time points (0, 4, 10, 20, 24, 36
and 48 h) and concentrations (0.5, 1.0, 2.5, 5.0, and 7.5 μM) using a
ﬂuorescence-based assay. For the majority of time points, there were
minimal differences (± 2%) in cell viability in comparison to the
untreated (no PPMO) control at thematching time point; for either the
P7- or P7-AMCA-conjugated VEEV 5′+ PPMO at a given treatment/time
point, this reduction in viability did not exceed 10%. For themajority of
the PPMO incubations, no statistically signiﬁcant decrease in viability
was detected in two way ANOVA (α=0.05) with Bonferroni pairwise
comparison to the untreated control (“No PPMO”) at the matching
concentration and time point, with the exception of the VEEV 5′+ (P7),
and the Scr (P7-AMCA) at the 1 μM concentration/24h time point (9%
reduction in viability for both).
Two PPMO efﬁciently inhibit recombinant alphavirus production in vitro
To assess if these PPMO could successfully inhibit alphavirus
replication, as well as to conﬁrm the utility of the recombinant full-
length Sindbis virus which expresses the luciferase (luc) reporter
protein (SinLuc) as a tool for monitoring anti-SINV compounds, we
evaluated SINV-targeting PPMO (Table 1) in this system. SinLuc virus
was harvested following electroporation of BHK cells with in vitro
transcribed SinLuc RNA. Prior to infection with SinLuc virus BHK cells
were treated with SINV P3-PPMO in the concentration range that was
demonstrated to be non-cytotoxic in the cell viability experiment
(shown in Fig. 2A). For quantitative comparison, statistical analysiswas
performed to evaluate the luc levels for all groups (PPMO or untreated
control at all concentrations via two way ANOVA, α=0.05) as well as
pairwise comparison of luc levels for SINV PPMO treatments or
untreated (“No PPMO”) at each concentration to the corresponding Scr
treatment (Bonferroni's post-test,α=0.05). Dose-responsive inhibition
of SINV replication, as represented by luc readings, was observed for
both the SINV 5′+ PPMO (Fig. 3A, right panel) and SINV AUG PPMO (3A,
left panel). For the SINV AUG PPMO, at 5, 7.5 and 10 μM this reduction
was in the range of 70–90% relative to Scr and was statisticallyTable 1
PPMO sequences and target locations
Legenda PPMO Sequence (5′ to 3′) Region of PPMO target location
A SINV 5′+b CAATAGTGTGTACTACGCCGTC 5′ terminus of SINV genome
B SINV 3′+b GTTAAAAACAAAATTTTGTTG 3′ terminus of SINV genome
C SINV 5′−b CAACAAAATTTTGTTTTTAAC 5′ terminus of SINV antigenome
D SINV 3′−b GACGGCGTAGTACACACTATTG 3′ terminus of SINV antigenome
E SINV AUGb GGCTTCTCCATTGTGATGGTAG AUG of SINV genome
F SINV sgPb CTCTATTCATGGTGGTGGTGT Subgenomic promoter of SINV
antigenome
A VEEV 5′+c,d GCTTCTCTCATGCGCCGCCCAT 5′ terminus of VEEV genome
E VEEV
AUGc
GAACTTTCTCCATTTTGGGTAG AUG of VEEV genome
– Scrd,e AGTCTCGACTTGCTACCTCA Random sequence
– HRV 5′+b CAAAGGTACATAGTACCAGAG 5′ terminus of HRV genome
– HRV CREb GTCTGTTTCGTTTTCTCAACG Cis-acting replication element
(CRE) of HRV
a The letter designations indicate the target location in the alphavirus genome, as
shown in Fig. 1.
b PPMO conjugated to P3 peptide.
c PPMO conjugated to P7 peptide.
d PPMO conjugated to P7 and to 7-amino-4-methylcoumarin-3-acetic acid (AMCA).
e PPMO conjugated to either P3 or P7 peptide.signiﬁcant (p-valuesb0.01). For the SINV 5′+, a reduction of 85–100%
with the dose tested in the range of 0.5–10 μM was signiﬁcant (p-
valuesb0.001). In contrast, the level of inhibitionproduced by the SINV
5′-, 3′+ and 3′- PPMOwas similar at all concentrations, and these levels
were signiﬁcantly different from Scr PPMO (p-valuesb0.01); however,
this reduction (%) did not appear to be dose dependent. For the SgP, no
signiﬁcant differences were detected at the majority of the concentra-
tions tested, with the exception of 0.1 and 7.5 μM. However, at 0.1 μM,
for all groups (PPMO or untreated controls), the luc values were
generally higher relative to Scr, butwere not statistically different from
Scr (p-valuesN0.05). Thus, signiﬁcant dose-responsive inhibition was
observed for the SINV 5′+ and SINV AUG PPMO.
PPMO inhibit infectious Sindbis virus production in vitro
To assess the ability of PPMO to inhibit production of infectious
alphavirus in cell culture, BHKcell infectionwithwild typeSINV (Fig. 3B,
panels i) was performed under conditions similar to those used for the
SinLuc virus experiments (shown in Fig. 3A). SINV-infected BHK cells
were incubated with SINV 5′+, SINV AUG, SINV sgP, or SINV 3′+ PPMO
and virus production level was determined by plaque assay of
supernatants obtained at 24 hpi (Fig. 3A). A statistically signiﬁcant
reduction in titer resulted fromSINV5′+ andSINVAUGPPMOtreatment
(Dunnett's test of PPMOvs.mock treatment, pb0.01 for each); at 1 μM, a
reduction of 86% and 88% was measured for SINV 5′+ and SINV AUG,
respectively; at 5 μM, the level of inhibition was higher (pb0.01): 99%
and 89%, respectively. In contrast, SINV sgP and SINV 3′+ PPMO did not
affect the SINV levels signiﬁcantly (pN0.05).
To further assess the virus speciﬁc effects of the two SINV-speciﬁc
PPPMO that inhibited viral production in these prior experiments, Vero
cells were infected at an moi of 0.1 with the control viruses, VSV and
VEEV (TC-83), and then incubated with the SINV AUG and SINV 5′+
PPMOat a concentrationof 5 μM,or as a control, Vero cellwere infected,
but left untreated (“no PPMO”, Fig. 3B, panel ii). For VSV, titers were
most variable at the earlier time point of 8 h, with a maximum
difference in titer from the untreated control of 1.4 log10 PFU/ml (SINV
AUG); at the later time point of 24 h, VSV titers were similar for all the
PPMO,with amaximumdifference of 0.71 log10 PFU/ml. For TC83, titers
weremore consistent at 8 h,withmaximumdifference of∼1 log10 PFU/
ml; at 24 h, the maximum difference was ∼2 log10 PFU/ml. No obvious
trend in non-speciﬁc inhibition by any of these PPMO was evident.
PPMO directed at 5′ sequence elements inhibit SINV translation
The effect of PPMO on viral translation was assessed following
SINV 5′+, SINV AUG, SINV sgP or SINV 3′+ PPMO treatment of SINV-
infected cell cultures. Quantiﬁcation of the level of viral capsid (C) and
envelope (E1) proteins in 35S-labeled BHK cell lysates obtained at
24 hpi and resolved by SDS-PAGE indicates that the SINV 5′+ and the
SINV AUG PPMO strongly inhibited viral translation, with capsid
protein expression at 1.2% and 16% of the infected, untreated cells
(Fig. 3C). In contrast, incubationwith the SINV sgP and SINV 3′+ PPMO
produced little inhibition of viral translation, with capsid expression
at 92% and 86%, respectively, relative to the infected, mock-treated
cells. These results are consistent with the SINV 5′+ or SINV AUG
PPMO-mediated inhibition of recombinant (SinLuc, Fig. 3A) and wild
type SINV (Fig. 3B).
PPMO are potent inhibitors of viral translation
In vitro transcribed SINV RNA was used to program rabbit
reticulocyte lysate (Fig. 3D) in the presence of different ratios of
molar excess of SINV (Fig. 3D, panel i) and human rhinovirus type 14
(HRV14)-speciﬁc PPMO (Fig. 3D, panel ii). None of the HRV14 speciﬁc
PPMO inhibited SINV-driven translation. These results were identical
to that observed for two other HRV-targeting PPMO (R. Rijnbrand,
361S. Paessler et al. / Virology 376 (2008) 357–370manuscript in preparation). In contrast, the SINV 3′+ and SINV sgP
PPMO did not inhibit viral translation. SINV 5′+ and AUG showed
strong inhibition of viral translationwith SINV AUG, even inhibiting at
a 1:1 molar ratio. SINV 5′+ inhibited translation, but less efﬁciently
than the other PPMO tested, with some detectable protein expression
still evident in the presence of 10-fold molar excess.
PPMO inhibition of VEEV production in vitro
Based on the observed anti-SINV effectiveness of the SINV 5′+ and
SINV AUG PPMO against SINV in the above experiments, PPMO
designed to target the corresponding regions of VEEV were then
synthesized (Fig. 1). While the SINV PPMO had been synthesized with
P3 as the peptide component of the PPMO, the two VEEV-speciﬁc
antisense and the Scr control sequences were prepared as P7-PPMO.
The more-recently developed P7 was selected as the conjugation
peptide for the VEEV experiments, as it has been reported to transport
PPMO into cells with equal or greater ability than that provided by P3
peptide (Abes et al., 2006), yet is more stable (Youngblood et al., 2007),
less affected by serum (Deas et al., 2005) and less cytotoxic than P3
(Abes et al., 2006).
Vero cells were infected with various strains of VEEV or, as a
control, with VSV, prior to the addition of VEEV 5+, VEEV AUG or Scr
PPMO (Fig. 4A) at 5 μM. At 8 (left panel) or 24 hpi (right panel), the
supernatant was harvested for analysis of viral titer via plaque assay.
At both time points, viral titers of the VEEV 5+ or VEEV AUG-treated
cultures were below the limit of detection (0.6 log10 PFU/ml) for all
VEEV strains. In contrast, for the VSV control, viral production was
relatively unaffected by PPMO treatment; VSV levels were in the range
of 2–3 log10/ml and 5–8 log10 PFU/ml at 8 and 24 hpi, respectively. The
relative virus production for the different VEEV strains was similar at
both time points, however, the titers at 24 h were ∼5 log10 higher.
These experiments indicate that the VEEV 5′+ PPMO was effective at
reducing the virus production at 8 and 24 hpi for multiple strains of
VEEV, despite amoderate level of non-speciﬁc activity. Dose–response
experiments with TC83 were subsequently performed at the same
moi and incubation time, but including additional sampling time
points and concentrations using the VEEV 5′+ P7-PPMO conjugated to
the ﬂuorescent label, AMCA (Fig. 4B), or as control, the P7-AMCA-
conjugated Scr. At the lower doses of 0.5 and 1.0 μM, no signiﬁcant
reduction in viral titer was detected for the 5′+ PPMO-treated cells in
comparison to Scr. However, the 5′+ PPMO treatment resulted in a
modest reduction at a dose of 2.5 μM, and marked reduction at doses
of 5, 7.5 and 10 μM. No reduction in the virus production pattern was
observed for Scr-treated cells compared to untreated VEEV-infected
cells at any of the concentrations or time points tested.
To assess the robust nature of the observed qualitative differences
in inhibition by the VEEV PPMO, additional analysis of the effects on
VEEV (TC-83) was performed (Fig. 4C). Vero cells were infected with
VEEV or, as a control, with VSV, for 1 h (+1 h) prior to the addition of
VEEV 5+, VEEV AUG or Scr PPMO at 5 μM. Supernatants were collected
at 8 and 24 h for determination of the level of virus production via
plaque assay, which was performed in eight replicates. A statistically
signiﬁcant difference in titer level was detected between VEEV 5′+
PPMO and VEEV AUG in pairwise comparison to either the Scr or
untreated (“No PPMO”) control (Bonferroni, pb0.001); for VEEV 5′+, a
reduction of 65–68% and 43–45% was detected at 8 and 24 h,
respectively, whereas a moremodest reduction of 23–29% and 21–24%
was detected for VEEV AUG at these time points (Fig. 4C, panel ii). At
8 h, a small (but statistically signiﬁcant) titer increase was detected for
Scr treatment in comparison to untreated (“No PPMO”), however,
there was no signiﬁcant difference at 24 h (pb0.05).
Treatment of combined VEEV 5′+ and VEEV AUG was evaluated at
two concentrations, 7.5 mM and 10 μM (each PPMO), as shown in
Fig. 4D. Vero cells were infected with VEEV (TC-83) or, as a control,
with VSV, for one h (+1 h) prior to the addition of the combined VEEV.Supernatants were collected at 8 and 24 h (and for VSV, at 48 h) for
determination of the level of virus production. For the treatments with
combined VEEV PPMO, the percent inhibition relative to VEEV-
infected, untreated Vero cells (“No PPMO”), as shown in the table
(Fig. 4D, bottom), was similar at both time points and concentrations;
48–51% for 5 μM of each PPMO and 46–48 for 7.5 μM of each. In
contrast, for VSV, overall lower percent inhibition resulted from
treatment with combined PPMO; 4 and 13% inhibition at 8 and 24 h,
respectively, for 5 μM (each PPMO), and 6 and 4% inhibition, res-
pectively, at 8 and 24 h for 10 μM (each PPMO); no substantial
difference were seen at 48 h (no inhibition and 6% inhibition for 5 and
10 μM).
Combined intranasal and subcutaneous PPMO treatment protects mice
against lethal VEEV infection
The animal model of VEEV using infection of NIH Swiss mice by the
highly virulent ZPC738 strain is well-described (Paessler et al., 2003,
2006). Mice develop encephalitis/paralysis and typically succumb to
disease between 6 and 10 days post-infection. Our prior experience
with intranasal delivery of vaccines against VEEV in mice (Anish-
chenko et al., 2006; Ni et al., 2007) suggested to us that a novel
administration route of PPMO using a combination of intranasal and
subcutaneous delivery would potentially be effective against neu-
roinvasive viruses such as VEEV. Other studies have reported that the
use of 200 μg/dose (10 mg/kg) delivered via intraperitoneal (i.p.)
against WNV (Deas et al., 2007) or via intravenous (i.v.) route against
coxsackievirus B3 virus (Yuan et al., 2006) was nontoxic and provided
antiviral effects.
We evaluated the antiviral efﬁcacy of combined VEEV 5′+ and VEEV
AUG PPMO treatment by measurement of survival and viral titers in
the brain and peripheral organs (Fig. 5) of mice receiving treatment
with PPMO prior to (+pre) or following (+post) infection with 103 PFU
of virulent VEEV. No deaths occurred in the group of uninfected mice
receiving VEEV-speciﬁc PPMO before and after infection (8/8, 100%
survival), indicating that this dosing regimen was well-tolerated. In
the VEEV-infected groups, there were no survivors in the group
receiving both pre- and post-infection treatment with Scr PPMO (0%,
0/10). In contrast, 100% (8/8) of the group receiving both pre- and
post-infection treatment with VEEV 5+ and VEEV AUG PPMO survived
while 63% (5/8) of the group receiving only post-infection treatment
with the VEEV-speciﬁc PPMO survived. There was a statistically
signiﬁcant difference among all survival curves (logrank, pb0.0001).
Statistical comparison of survival between the group receiving PPMO
treatment both before and after infection and the untreated VEEV-
infected control showed a statistically signiﬁcant difference (α=0.05;
Fisher's Exact, p=0.0002), as did the group receiving PPMO treatment
only after infection, in comparison with the untreated VEEV-infected
control group (α=0.05; Fisher's Exact, p=0.0256).
Infectious virus levels in the brain and peripheral organs of VEEV-
infected mice are reduced following combined pre- and post-infection
PPMO treatment
We evaluated the VEEV titers at three early post-infection time
points (2, 3 and 4 dpi) in the brain and peripheral organs of four
randomly selected mice that were treated with i) PPMO diluent (mock
treatment), ii) VEEV 5′+ PPMO before and after infection, and iii) VEEV
5′+ PPMO after infection (Fig. 5B). At all time points tested, VEEV was
undetectable in the blood, brain, and peripheral tissues (liver, lung and
spleen) of mice that received the VEEV 5′+ PPMO pre- and post-
infection (+pre/+post) treatments. In mice that received only post-
infection (−pre/+post) 5′+ PPMO treatment, reduction in VEEV titer
varied, depending upon the tissue examined. In the blood, VEEV titers
for the VEEV 5′+ treated groups were similar to those of the mock-
treated mice at days 2 and 3 pi, but over 2 logs lower than mock-
Fig. 3.
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Fig. 3. PPMO antiviral activity against the alphavirus, SINV. A) Dose–response inhibition of recombinant SINV production. BHK cells were infected with SinLuc at a multiplicity of
infection (moi) of ∼0.03, followed by treatment with the indicated concentrations of SINV AUG, SINV sgP or Scr PPMO (left) or SINV genomic termini targeting PPMO (right) for 24 h.
Luciferase (Luc) levels were measured in triplicate, as described in Materials and methods. The average and standard deviation are shown. Statistical analysis of luciferase levels of
SINV PPMO vs. Scr treatment (two-way ANOVA, α=0.05; pairwise comparison via Bonferroni post-test) was performed and results are described in the text. B) Dose–response
inhibition of wild type SINV. Panel i–ii) Effect of SINV PPMO on SINV production. BHK cells were infectedwith SINV at anmoi of ∼0.03 and treated at 1 hpi with the indicated PPMO (1
or 5 μM, panels i and ii, respectively). At 24 hpi, the virus levels in supernatant samples were determined by plaque assay. Supernatants were analyzed in quadruplicate (1 μM) or
triplicate (5 μM). The results of one representative experiment out of two performed is shown. Statistical analysis was performed using one-way ANOVA (α=0.05) with Dunnett's
Multiple Comparison Test in pairwise comparison of each PPMO-treated group relative to the mock control. Statistically signiﬁcant differences in Dunnett's test are indicated by an
asterisk (⁎p-valueb0.01) and the percent reduction is shown. Panel iii) Effect of SINV PPMO on two control viruses, VSV and TC83. Vero cells were infectedwith VSV or VEEV (TC83) at
an moi of 0.1 and treated at 1 hpi with the indicated PPMO at 5 μM. At 8 and 24 h, the virus production levels were determined by plaque assay. Viral titration of untreated, infected
Vero cells (“No PPMO”) was also performed. The result of a single experiment is shown. C) Inhibition of viral protein expression by SINV-speciﬁc PPMO. BHK cells were treated with
the indicated PPMO starting at 1 h after infectionwith SINV (moi of 0.03). At 24 hpi the cells were incubated with 35S-methionine for 1 h, and cell lysates then analyzed by SDS-PAGE.
The molecular weight marker is shown. Viral capsid (C) and envelope protein (E1) and apparent molecular mass are indicated by the arrows. The percentage of C expression, relative
to the mock-treated control, as determined by densitometry, is shown numerically under the lanes. D) Inhibition of viral translation by SINV-speciﬁc PPMO. In vitro transcribed SINV
RNA was translated in rabbit reticulocyte lysates in the presence of a molar excess of the indicated PPMO as described in Materials and methods. Samples were separated by SDS-
PAGE and visualized by phosphor imager.
363S. Paessler et al. / Virology 376 (2008) 357–370treated on day 4 (Fig. 5B, panel i). In the brain, the VEEV 5′+ group
treated following infection (−pre/+post) showed higher titer at day 2,
but lower titer at days 3 and 4 compared to the mock-treated group
(Fig. 5B, panel ii); notably, on 4 dpi, VEEV titers for the −pre/+post
VEEV 5′+ PPMO was reduced to 80 PFU/g tissue, a level near the limitof detection in this assay of 60 PFU/g. Compared tomock-treatedmice,
the average liver titers in the mice receiving −pre/+post VEEV 5′+
PPMO following infectionwas about 1 log10 higher at 2 dpi, and about
2 log10 less at 3 and 4 dpi, (Fig. 5B, panel iii). Spleen titers in the group
receiving VEEV 5′+ treatment following infection were similar to
364 S. Paessler et al. / Virology 376 (2008) 357–370mock-treated mice at 2 dpi, somewhat lower than mock at 3 dpi, and
considerably lower (undetectable) than mock at 4 dpi (Fig. 5B, panel
iv). Lung titers were similarly low for mice treated −pre/+post VEEV
with 5′+ and mock-treated mice at 2 and 3 dpi, while at 4 dpi, mock-
treated mice had an average titer of ∼4 log10 while both PPMO
treatment groups had undetectable titers (Fig. 5B, panel v).
Discussion
VEEV is a highly lethal alphavirus that is of considerable human
and veterinary health importance. No effective human vaccine or
therapeutic against VEEV is presently available. Alphaviruses exhibit
robust replication in both cell culture and in animals, and, as such,
provide an excellent system to investigate the antiviral efﬁcacy and
speciﬁcity of PPMO. Here we have demonstrated the potent inhibition
of both SINV and a variety of VEEV strains in cell culture with PPMO
targeted to the 5′ region of the genomic RNA. Importantly, we were
able to prevent VEEV-induced lethal encephalitis in a mouse model.
In this study, we used an alphavirus of low pathogenicity to
humans, Sindbis virus, to guide our design of PPMO against the highly
pathogenic VEEV. The strategy was successful, as PPMO designed to
target the corresponding sequence-regions in VEEV were highly
effective in vitro and in vivo against VEEV. Furthermore, results with a
luciferase-expressing SINV showed that the SINV-speciﬁc PPMO were
strong inhibitors of viral replication (Fig. 3A). The obtained results
were consistent with results using wild type SINV (Fig. 3B), validating
the utility of SinLuc as a drug screening reagent.
Of the six PPMO designed against SINV, only the two targeting the 5′
region of genomic RNAwere effective at inhibiting viral replication. The
antiviral efﬁcacy of PPMO targeted to various locations in the 5′ end of
the genome of positive-strand RNA viruses has been observed for
Nidoviruses (Neumanet al., 2005; van denBorn et al., 2005; Zhanget al.,
2006), Flaviviruses (Deas et al., 2005; Kinney et al., 2005), and
Picornaviruses (Vagnozzi et al., 2007; Yuan et al., 2006). It remains
undetermined why four of the six SINV PPMO in this study were
relatively ineffective. Future studies may evaluate other regions of
alphavirus sequence as prospective PPMO targets, including the 5′
terminal- and AUG-regions of the subgenomic RNA. Results from cell
culture (Fig. 3C) and in cell-free translation assays (Fig. 3D) indicate that
both active PPMO identiﬁed in this study can directly interferewith viral
translation. The lack of activity by several PPMO incidentally provides
conﬁrmation of the speciﬁcity of the inhibitory action of the effective
PPMO. In addition, these experiments did not reveal any non-speciﬁc
toxicity associated with PPMO chemistry, which would be reﬂected in
overall lowered luciferase (Fig. 3A), plaque (Fig. 3B), or viral protein
production (Fig. 3C) in comparison with untreated or Scr controls.
Further evidence of the lack of toxicity of this compound is provided by
cell viability assays for all PPMO used (Fig. 2), the relatively low
inhibitory activity of VEEV-speciﬁc PPMO against VSV (Fig. 4A), the
control (Scr) PPMO employed throughout this study, and the uncom-
promised health of PPMO-treated (uninfected) mice (Fig. 5A).Fig. 4. PPMO antiviral activity against pathogenic alphaviruses. A) PPMO inhibition of multip
(TC-83, SH3, ZPC738, or 68U201) or, as a negative control, with vesicular stomatitis virus (VSV
supernatants were harvested for analysis of viral titer via plaque assay. The VEEV serotype is
68U201 and ZPC738 are enzootic strains. The horizontal line depicts the limit of detection. Ast
single experiment is shown. B) PPMO dose–response inhibition of VEEV. Vero cells were infe
P7-AMCA-conjugated PPMO at doses in the range of 0.5 to 10 μM. At various time points post
plaque assay. The result of a single experiment is shown. C) Effect of VEEV PPMO on VEEV and
VEEV (TC-83 strain), or as a control, with VSV, for 1 h prior to the addition of the indicated
analysis of viral titer via plaque assay, performed in eight replicates at each time point for
comparing all treatments using one-way analysis of variance (α=0.05, GraphPad Prism). P
Bonferroni post-test. Bars with asterisk indicate a statistically signiﬁcant difference (Bonfer
100⁎ (VEEV PPMO-average control)÷average control. A summary table showing the average
D) Effect of combined VEEV 5′+ and VEEV AUG PPMO on VEEV. Vero cells were infected at a m
of the indicated P7-AMCA-conjugated PPMO at 7.5 and 10 μM (each PPMO). Supernatants wer
plaque assay. The result of a single experiment is shown.Both the VEEV 5′+ and AUG PPMO were highly effective against
multiple strains of VEEV in cell culture (Fig. 4A). This is not surprising,
considering the high to perfect sequence conservation of the PPMO
target sites among the VEEV strains tested. Similar sequence
conservation is present in all the VEEV strains available from GenBank
(data not shown), and indicates that these two PPMOmay represent a
useful antiviral treatment for enzootic as well as epidemic strains of
VEEV. Studies designed to target the corresponding conserved
sequences in two other major groups of encephalitic alphaviruses,
EEEV and WEEV, are currently in progress.
Complete protection was provided against otherwise lethal VEEV-
induced disease in the murine model when antisense PPMO were
administered both before and after infection. However, post-infection
PPMO treatment conferred partial protection, indicating that PPMO
may be useful even in a strictly therapeutic setting. Tissue titer data
(Fig. 5B) reﬂected the survival proﬁles (Fig. 5A) in the mouse efﬁcacy
experiment, and clearly implicates reduction in virus production as
the mechanism of efﬁcacy of the antisense PPMO. The novel PPMO
administration scheme employed in this study (subcutaneous com-
bined with intranasal) is deserving further exploration, as it may be
that modiﬁcation of the relative proportions and doses of PPMO
delivered by these two inoculation routes could be ﬁne-tuned to
further enhance efﬁcacy. Notably, the two modes of administration
employed here are preferable to intravenous injection for prospective
human treatment. It will also be of interest to explore PPMO efﬁcacy
against VEEV strains other than ZPC738 in this same mouse model, or
against VEEV in other animal models.
Materials and methods
Preparation of PPMO
All PMO were synthesized at AVI BioPharma Inc. (Corvallis, OR) by
methods previously described (Summerton and Weller, 1997). SINV-
speciﬁc PMO were covalently conjugated, at the 5′ end, to the
arginine-rich peptide NH2-R9F2C-CONH2 (abbreviated ‘P3’), and VEEV-
speciﬁc PMO to NH2-(RXR)4XB-CONH2 (X=6-aminohexanoic acid,
B=Beta alanine) (abbreviated ‘P7’). The conjugation, puriﬁcation and
analysis of PPMOwere performed by procedures previously described
(Abes et al., 2006; Moulton et al., 2004). Additionally, P7-PPMO
versions of the VEEV 5+ and Scr were prepared with the ﬂuor AMCA
(7-amino-4-methyl-3-coumarinyl acetic acid; Sigma-Aldrich, St.
Louis, MO) conjugated to the 3′ end by methods similar to those
described previously for carboxyﬂuorescein conjugation to PMO
(Moulton et al., 2003).
Design of speciﬁc PPMO
PPMO of 21–22 bases in length were designed to target, by
complementary base pairing, regions in SINV or VEEV that have been
identiﬁed as important in the viral RNA synthesis or translation. Thele VEEV strains. Vero cells were infected at a moi of 0.1 with the indicated strain of VEEV
) for 2 h prior to the addition of the indicated PPMO at 5 μM. At 8 (left) or 24 hpi (right),
indicated in parentheses. SH3 and TC-83 are epizootic (or epizootic derivative) strains;
erisk (⁎) indicates that no virus was detected for any sample in that group. The result of a
cted at a moi of 0.1 with VEEV (TC-83 strain) for 1 h prior to the addition of the indicated
-infection (indicated in graph), supernatants were harvested for analysis of viral titer via
on the control virus, VSV (eight replicates). Vero cells were infected at a moi of 0.1 with
P7-AMCA-conjugated PPMO at 5 μM. Supernatants were harvested at 8 and 24 hpi for
VEEV or VSV. Statistical analysis was performed on log10-transformed viral titer values
airwise comparison of the log10-titer values by treatment group was performed using
roni, p-valueb0.001). The average percent change was calculated from log10 titers as:
percent change, relative to either the untreated (“No PPMO”) or Scr controls is shown.
oi of 0.1 with VEEV (TC-83 strain), or as a control, with VSV, for 1 h prior to the addition
e harvested at 8 and 24 hpi (and for VSV, at 8, 24, and 48 hpi) for analysis of viral titer via
365S. Paessler et al. / Virology 376 (2008) 357–370PPMO sequences and name designations are speciﬁed in Table 1 and a
schematic representation of their target locations is provided in Fig. 1.
Additionally, a 20-mer PMO of random sequence having 50% G/C
content (named 'Scr’) was conjugated to either P3 or P7 peptide for
use as a control for non-sequence-speciﬁc activity of the two
respective PPMO chemistries. To preclude unintentional hybridization
events, antisense and negative control PPMO sequences wereFig. 4screened via BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) against
primate and murine mRNA sequences. In addition, the negative
control was screened against all published alphavirus sequences.
PPMO targeted to human rhinovirus type 14 (HRV14) were used as
additional controls for SINV in vitro translation experiments. Prior to
use, lyophilized PPMO were suspended with ﬁlter-sterilized distilled
water to a concentration of 1–2 mM, and stored at 4 °C..
Fig. 4 (continued ).
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The following VEEV strains were used: ZPC738 (Roehrig and
Bolin, 1997; Wang et al., 1999), TC-83 (Berge et al., 1961; Kinney etal., 1989), SH3 (Rico-Hesse et al., 1995), and 68U201 (Oberste et al.,
1996; Scherer et al., 1970). Alphavirus stocks were generated by
growth in cell culture and the viral titer of the stock was obtained
via plaque assay, as described previously (Paessler et al., 2003).
367S. Paessler et al. / Virology 376 (2008) 357–370Sindbis virus (SINV, TE12) was obtained by electroporation of BHK
cells with RNA derived from pTOTO1101 (Rice et al., 1987). A clone
containing an infectious copy of SinLuc was a gift from Ilya Frolov
(UTMB). Vesicular stomatitis virus (VSV) was obtained from Scott
Weaver.
Cells
The baby hamster kidney cell line, BHK21 (BHK), (American Type
Culture Collection, Manassas, VA) and Vero cells were maintained
at 37 °C, 5% CO2 in Dulbecco's Modiﬁed Eagle's Medium (DMEM,
Hyclone, Logan, UT) with 10% fetal bovine serum and antibiotics.
Viability assay
For the P3-conjugated SINV-speciﬁc PPMO, spectrophotometric
measurement of the reduction of MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) to formazan was performed
according to the manufacturer's protocol (Sigma, St. Louis, MO)
(Mosmann, 1983). BHK cells at 80% conﬂuency were incubated with
the indicated PPMO in the range of 0.1–20 μM for 24 h. The pro-
duction of formazan relative to mock-treated cells was used to assess
PPMO toxicity. For the P7- and P7-AMCA-conjugated VEEV-speciﬁc
(VEEV 5′+ or VEEV AUG) and the control (Scr) PPMO, viability assay
measuring the conversion of resazurin to resoruﬁn was performed
using CellTiter-Blue® Reagent (Promega, Madison, WI). Brieﬂy,
Vero cells were incubated with PPMO concentrations in the range
of 0–7.5 μM for 1 h, afterwhich the incubationmediawas removed and
cells incubated for various time periods (0, 4, 10, 20, 24, 36 and 48 h).
Each treatment was performed in quadruplicate wells. At the
designated time point, 20 μl of CellTiter-Blue was added to each well.
Plates were then incubated in accordance with the manufacturer's
recommendations, and read on a Bio-Tek FLx800 ﬂuorescent plate
reader (560Ex/590Emnm).
In vitro inhibition of SINV replication
In vitro transcription of pSinLuc and electroporation of RNA into
BHK cells was performed to generate viral stocks for infection, as
described previously (Liljestrom and Garoff, 1991). BHK cells were
infected with SINV or SinLuc at a multiplicity of infection (moi) of
∼0.03 and treated at 1 h post-infection (hpi) with the indicated
PPMO. The cells were then incubated for 24 h and virus production
was determined via plaque assay of virus production or via
quantitative luciferase assay (Promega, Madison, WI). In vitro
translation reactions were performed using rabbit reticulocyte lysate
(Promega), as described by the supplier. Lysates were programmed
with 125 ng RNA/10 μl lysate and were resolved by SDS-PAGE and
analyzed by phosphor imager. Statistical analysis of the average
luciferase levels obtained from triplicate measurement was per-
formed using two-way analysis of variance (ANOVA, α=0.05) with
pairwise comparison of each SINV PPMO with Scr using Bonferroni's
post-test using GraphPad Prism 4.0 (GraphPad Software, San Diego
California USA). Statistical analysis of the level of virus production
(log10 transformed) obtained from quadruplicate (1 μM) or triplicate
(5 μM) values was performed using one-way ANOVA (α=0.05) with
Dunnett's Multiple Comparison Test for pairwise comparison of each
PPMO-treated group to the mock-treated control (GraphPad Prism
4.0). To further evaluate potential non-speciﬁc effects of the SINV
PPMO, experiments were performed using Vero cells infected with
VSV or VEEV (TC-83) at an moi of 0.1 and then treated with the
SINV 5′+, SINV AUG or Scr PPMO at 1 h post-infection (+1 h). Cell
supernatants were harvested at 8 and 24 hpi for determination of
viral titer via plaque assay. In parallel, supernatants were also
collected from untreated, infected Vero cells (“No PPMO”) for viral
titration.Viral protein expression
BHK cells were infected with SINV at an moi of 0.03 and treated
with PPMO at 1 hpi. 35S-methionine was added to cells at 24 hpi and
cells harvested 1 h later. Cell lysates were prepared by detergent lysis
and analyzed by SDS-PAGE (10%) followed by densitometry (Storm
840 gel imaging system). Viral proteins were identiﬁed (E1, ∼52kDa;
C, ∼32kDa) using a 14C labeled molecular weight marker (Amersham
Life Science, Arlington Heights, IL), as published previously (Paessler
et al., 2003).
In vitro inhibition of VEEV replication
Vero cells were infected at a moi of 0.1 with the indicated strain
of VEEV (TC-83, SH3, ZPC738, or 68U201), or, as a negative control,
with VSV and incubated for 1–2 h (+1 or +2 h, as indicated in the
ﬁgure legends) prior to the addition of the indicated VEEV PPMO
(AUG, VEEV 5′+, or Scr). Virus containing media was removed and
the indicated PPMO was added at a concentration of 5 μM.
Supernatant was harvested at 8 or 24 hpi for analysis of viral titer
via plaque assay (Paessler et al., 2003). Statistical analysis of virus
titers (log10 transformed) obtained from eight replicate values
(where indicated in ﬁgure legend) was performed using one-way
ANOVA (α=0.05) with Bonferroni's Multiple Comparison Test for
pairwise comparison of each group. Combined PPMO treatment was
performed as described above. Brieﬂy, Vero cells were infected at a
moi of 0.1 with the indicated strain of VEEV (TC-83), or as a control,
with VSV, and incubated for +1 h prior to the addition of 7.5 or
10 μM (each PPMO) of combined VEEV AUG and VEEV 5′+. As a
control, untreated Vero cells were incubated in parallel. Plaque assay
of supernatants obtained at 8, 24, and 48 h (the latter for VSV only)
was performed.
Mice
Nine-week-old NIH Swiss mice were purchased from Harlan
Sprague Dawley, Inc. (Indianapolis, IN), and allowed to acclimatize
for at least 1 week. All studies were approved by the UTMB
Institutional Animal Care and Use Committee and work with VEEV
was performed at the Biosafety Level-3 in accordance with UTMB
Health and Safety approval and guidelines. Mice were allowed food
and water ad libitum throughout the studies.
PPMO efﬁcacy in mice
Mice were treated with VEEV-speciﬁc PPMO (combined AUG and
5′+ in equal amounts) or the random control PPMO (Scr) in serum-
free DMEM at a dose per mouse of 40 μg via i.n. route and 160 μg
via s.c. route at time points pre- (2 doses: − 24 h and − 4 h,
indicated as “+pre”) and/or post-infection (5 doses: daily on day +1
through +5, indicated as “+post”). On day 0, the indicated groups
were infected with 103 PFU of virulent VEEV (ZPC738) via i.n. route.
Control groups consisted of the following: 1) VEEV-speciﬁc PPMO-
treated, VEEV-infected mice, and 2) VEEV-infected, but untreated
mice. Mice (N=8–10 per group) were monitored daily for death over
a 28-day period following infection. At 2, 3 and 4 days post-
infection (dpi), four animals per group were euthanized for harvest
of blood, brain and peripheral organs (liver, spleen and lung).
Infectious virus levels in the tissues were determined via plaque
assay, as described previously (Paessler et al., 2003). Statistical
analysis of survival for all groups over the indicated period was
performed using logrank test at a signiﬁcant level of αb0.05 in
GraphPad® Prism (San Diego, CA). For pairwise comparison of the
survival of treated and untreated (or mock-treated) groups Fisher's
Exact Test was performed at a signiﬁcance level of αb0.05 in
GraphPad® Prism.
Fig. 5.
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